Results from the at-home test kit are available
to HCPs and their patients through 1health
ChromaDex Corp. (NASDAQ:CDXC), the global authority on
nicotinamide adenine dinucleotide (NAD+) research with a focus on
healthy aging, launches the Niagen+ NAD+ Test Kit*, now available
exclusively through the company’s healthcare practitioner (HCP)
channel. This innovative test kit provides practitioners with a
reliable method for measuring patient blood NAD+ levels, helping
them create more personalized and effective patient protocols using
ChromaDex’s NAD+-boosting HCP products, Tru Niagen® and
Niagen+.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240723490080/en/
ChromaDex launches Niagen+ NAD+ Test Kit,
one of the most reliable methods for patients to measure and track
their NAD+ levels (Photo: Business Wire)
Tru Niagen is a suite of oral dietary supplements featuring
Niagen (patented nicotinamide riboside or NR), the most efficient
and high-quality NAD+ precursor available. Niagen+ features
pharmaceutical-grade Niagen (patented nicotinamide riboside
chloride or NRC) and will soon be available as Niagen IV and
injections exclusively at clinics from U.S. FDA 503B-registered
outsourcing facilities with a prescription. Representing a
significant advancement in intravenous NAD+ therapy, practitioners
are eager to provide Niagen IV therapy to patients.
Rob Fried, CEO of ChromaDex and Founder of Tru Niagen, noted,
"Our healthcare practitioners have requested a tool to measure
blood NAD+ levels, and we believe this is the best product now
available on the market."
Setting a new standard in analytical NAD+ measurement methods,
the Niagen+ NAD+ Test Kit features cutting-edge dried blood spot
(DBS) assay technology, ensuring the stability of NAD+ samples
during transport for precise and accurate results. Other test kits
use a less reliable DBS card, which requires adding a fixer
solution to stabilize NAD+, which often degrades during the DBS
drying process. With this innovative Niagen+ NAD+ test, HCPs can
provide patients with personalized and effective protocols by more
accurately tracking NAD+ changes over time.
Key Niagen+ NAD+ Test Kit features:
- Innovative test card technology: A unique blood spot
test card maintains the stability of NAD+ throughout the transport
process and ensures accurate measurement.
- Baseline and progress tracking: While each HCP will
determine the patient protocol, the test can be used to understand
NAD+ levels before Tru Niagen NAD+-boosting and/or Niagen IV and
injections to establish a baseline and again after NAD+ boosting
therapy to track changes.
- Validated, trusted results: Analyses are conducted at a
Clinical Laboratory Improvement Amendments (CLIA) and the College
of American Pathologists (CAP) accredited clinical genomics and
biochemical testing laboratory with expertise in mass spec-based
assays.
- Precision analysis: NAD+ measurements are conducted on
the blood sample affixed to the DBS card using the gold standard
analytical method, high-resolution liquid chromatography/tandem
mass spectrometry (LC-MS/MS).
How it works:
HCPs will provide patients with an at-home Niagen+ NAD+ Test
Kit, which patients will register on the 1health platform. Once
registered, the patient will follow the instructions within the kit
to procure a sample with the DBS card and send it to the lab using
a prepaid envelope. Results will be available to both patients and
doctors in about two weeks through 1health.
Mehdi Maghsoodnia, CEO at 1health, emphasized the critical role
of 1health’s platform in the successful launch of the Niagen+ NAD+
Test Kit. “We are proud to partner with ChromaDex to bring this
innovative testing solution to healthcare practitioners. Our robust
software seamlessly integrates with both the warehouse and the lab,
ensuring efficient fulfillment of kits and accurate delivery of
results. This collaboration provides invaluable insights for
practitioners aiming to optimize their patients' NAD+ levels,
enabling personalized and effective NAD+ boosting protocols, such
as Tru Niagen oral supplementation and soon Niagen IV and
injection, to maximize therapeutic outcomes.”
Practitioners can learn more about the test kit, view all HCP
products, and find research on clinical practice applications at
www.truniagenpro.com. To learn more about ChromaDex, please visit
www.chromadex.com.
*This product is not intended to diagnose, prevent, or treat a
condition. Measurements and statistics are intended for
informational and educational purposes only, to support general
health and wellness. This product has not been tested with
individuals with health conditions and has not been cleared or
approved by the U.S. Food and Drug Administration.
Forward-Looking Statements:
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities and Exchange Act of 1934, as
amended, including statements related to the Niagen+ NAD+ Test Kit,
now available exclusively through the company’s healthcare
practitioner (HCP) channel. Statements that are not a description
of historical facts constitute forward-looking statements and may
often, but not always, be identified by the use of such words as
"expects," "anticipates," "intends," "estimates," "plans,"
"potential," "possible," "probable," "believes," "seeks," "may,"
"will," "should," "could" or the negative of such terms or other
similar expressions. Risks that contribute to the uncertain nature
of these forward-looking statements include the impact of the
COVID-19 pandemic on our business and the global economy; our
history of operating losses and need to obtain additional
financing; the growth and profitability of our product sales; our
ability to maintain sales, marketing and distribution capabilities;
changing consumer perceptions of our products; our reliance on a
single or limited number of third-party suppliers; and the risks
and uncertainties associated with our business and financial
condition. More detailed information about ChromaDex and the risk
factors that may affect the realization of forward-looking
statements is set forth in ChromaDex's Annual Report on Form 10-K
for the fiscal year ended December 31, 2023, ChromaDex's Quarterly
Reports on Form 10-Q and other filings submitted by ChromaDex to
the SEC, copies of which may be obtained from the SEC's website at
www.sec.gov. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof, and actual results may differ materially from those
suggested by these forward-looking statements. All forward-looking
statements are qualified in their entirety by this cautionary
statement and ChromaDex undertakes no obligation to revise or
update this release to reflect events or circumstances after the
date hereof.
About ChromaDex:
ChromaDex Corp. (NASDAQ:CDXC) is the global authority on
nicotinamide adenine dinucleotide (NAD+), with a focus on the
science of healthy aging. The ChromaDex team, composed of
world-renowned scientists, works with independent investigators
from esteemed universities and research institutions around the
globe to uncover the full potential of NAD+. A vital coenzyme found
in every cell of the human body, NAD+ declines with age and
exposure to other everyday stressors. NAD+ depletion is a
contributor to age-related changes in health and vitality.
Setting the benchmark as the gold standard in scientific rigor,
safety, quality, and transparency, ChromaDex is the innovator
behind its clinically proven flagship ingredient, Niagen (patented
nicotinamide riboside, or NR), the most efficient and
superior-quality NAD+ booster available.
Niagen® is the active ingredient in ChromaDex’s consumer
products, sold as the brand Tru Niagen®, the number one
healthy-aging NAD+ supplement in the United States†. Clinically
proven to increase NAD+ levels, Tru Niagen is helping people around
the world transform the way they age (available at
www.truniagen.com).
ChromaDex’s robust patent portfolio protects NR and other NAD+
precursors. ChromaDex maintains a website at www.chromadex.com,
where copies of press releases, news, and financial information are
regularly published.
†Based on the top-selling dietary supplement brands by revenue
per the largest U.S. e-commerce marketplace (as of
3/1/2023-2/29/2024).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240723490080/en/
ChromaDex Media Contact: Kendall Knysch, Senior Director
of Media Relations & Partnerships 310-388-6706 ext. 689
kendall.knysch@chromadex.com
ChromaDex Investor Relations Contact: Ben Shamsian Lytham
Partners 646-829-9701 shamsian@lythampartners.com
ChromaDex (NASDAQ:CDXC)
過去 株価チャート
から 6 2024 まで 7 2024
ChromaDex (NASDAQ:CDXC)
過去 株価チャート
から 7 2023 まで 7 2024
